Evercore ISI raises IQVIA stock price target to $220 on improved pharma demand

Published 22/07/2025, 21:52
Evercore ISI raises IQVIA stock price target to $220 on improved pharma demand

Investing.com - Evercore ISI has raised its price target on IQVIA Holdings (NYSE:IQV) to $220.00 from $180.00 while maintaining an Outperform rating on the stock. According to InvestingPro data, IQVIA, currently trading at $187.33 with a market capitalization of $32.5 billion, appears undervalued based on its Fair Value analysis.

The research firm cited IQVIA’s improved demand environment in both pharmaceutical and biotech sectors, which contributed to solid second-quarter Research & Development Solutions (R&DS) revenues and improved bookings.

Technology & Analytics Solutions (TAS) also demonstrated better results with similar or improved quarter-over-quarter demand environments in analytics & consulting, real-world evidence, and technology.

Evercore ISI views IQVIA as positioned for further success in the second half of 2025, noting that management guidance appears reasonable for the third quarter with fourth-quarter growth supported by the improving demand environment and the restart of a previously delayed trial.

The new price target of $220 represents 12.5 times 2026 EBITDA and 17 times P/E, with the research firm highlighting IQVIA as a beneficiary of its "structurally-winning industry position" and continued momentum from an improving business cycle.

In other recent news, IQVIA Holdings Inc. reported its financial results for the second quarter of 2025, surpassing market expectations. The company achieved earnings per share of $2.81, which was above the projected $2.77. Additionally, IQVIA’s revenue reached $4.017 billion, exceeding the anticipated $3.96 billion. These results indicate a strong performance for the quarter. Analyst firms have taken note of IQVIA’s financial achievements, with some revisiting their assessments in light of the company’s robust earnings and revenue figures. The positive earnings report has contributed to increased investor confidence. These developments mark a significant period for IQVIA, reflecting its continued growth and resilience in the market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.